Introduction
============

Alpha-1 antitrypsin deficiency (AATD) is an autosomal codominant condition that remains the only consistent genetic risk factor for the development of chronic obstructive pulmonary disease (COPD). Historically, the deficient state was first identified by Laurell and Eriksson[@b1-tcrm-11-143] in the 1960s, who associated disease with the occurrence of emphysema. Following this, and less than a decade later, an association with liver disease was made.[@b2-tcrm-11-143]

Since then, our understanding of the condition has exponentially increased. The gene, which is located on chromosome 14q, codes for AAT and is a "serpin" family member, possessing key physiological roles in serine protease inhibition. While numerous AAT alleles have been described, nomenclature is based on gel electrophoresis migration patterns. For instance, those with higher isoelectric points are allocated letters nearer the start of the alphabet. While \>100 alleles have been described, they are generally divided into four groups based on serum level and function ([Table 1](#t1-tcrm-11-143){ref-type="table"}).[@b3-tcrm-11-143]

The highest incidence of AATD remains within Europe,[@b4-tcrm-11-143],[@b5-tcrm-11-143] with the first diagnostic step involving a screen for low serum concentrations of AAT. When levels are low, further analysis is performed to determine phenotype. This can involve phenotyping using isoelectric focusing or genotyping, or in some cases gene sequencing. Most mutations detected in clinical practice are deficient alleles homo- or heterozygous for the "S" or "Z" variants that correlate with the severity of the clinical manifestations observed. Null and dysfunctional states are less frequently encountered; however, increasing numbers of "null" mutations are described and named based on their first known location of detection ([Table 1](#t1-tcrm-11-143){ref-type="table"}).

While a variety of genetic mutations can occur within the AAT gene, the most common deficient states result from single amino acid substitutions: valine for glutamate at position 264 (Glu264Val) in the case of "S" variants and lysine for glutamate at position 342 (Glu342Lys) for "Z" variants.[@b6-tcrm-11-143] Owing to a reduced propensity to polymerize, the "S" protein variant results in milder deficiency states with reduced hepatocellular accrual as compared to the "Z" allele.[@b7-tcrm-11-143]--[@b9-tcrm-11-143]

Hepatic polymerization of Z AAT entraps the abnormal protein within the liver, with a subsequent diminished systemic release. As a result, pulmonary protease--antiprotease imbalance occurs, and proteases such as neutrophil elastase (NE) are unopposed in their actions in the lungs, resulting in pulmonary damage and emphysema. Pulmonary immunity is further compromised by the NE-mediated effects on complement receptors,[@b10-tcrm-11-143] CXCR1 receptors,[@b11-tcrm-11-143] immunoglobulins,[@b12-tcrm-11-143] ciliary motility,[@b13-tcrm-11-143] and antiproteases such as secretory leucoprotease inhibitor, and elafin.[@b14-tcrm-11-143],[@b15-tcrm-11-143] AATD-associated liver disease is linked to the hepatic polymerization of the Z AAT protein. In the normal physiological state, cells clear abnormally folded proteins after they are identified. In AATD, however, there is a significant imbalance between the abnormal protein folding load and the cell's ability to process this load. Hepatic endoplasmic reticulum (ER) stress results, causing a multitude of effects including the ER overload response, the unfolded protein response, and apoptosis.[@b16-tcrm-11-143]

Clinical manifestations of AATD
===============================

Pulmonary disease
-----------------

The major clinical features in AATD include pulmonary and hepatic diseases. The fundamental basis of AATD-associated pulmonary disease is early-onset panacinar emphysema observed in a basal distribution.[@b17-tcrm-11-143],[@b18-tcrm-11-143]

Most pulmonary disease associated with AATD coupled with either a current or previous history of cigarette smoking, usually presents in the third decade of life.[@b19-tcrm-11-143]--[@b21-tcrm-11-143] COPD has been demonstrated in three-quarters of Z AATD subjects with a median age of 52 years.[@b22-tcrm-11-143] While the natural history of the condition is unclear, it is predicted that a significant proportion of individuals with a current diagnosis of smoking-related emphysema remain undiagnosed with regard to AATD. The majority of individuals with this disease do have some history of smoking, which in itself has been shown to reduce survival in AATD sufferers by up to two decades.[@b19-tcrm-11-143] However, it should be noted that individuals with AATD can have significant obstructive lung disease even in the absence of a smoking history.

Symptom frequency in individuals with AATD was assessed in the population recorded within the National Heart, Lung, and Blood Institute (NHLBI) registry. Dyspnea was most common, followed by wheeze and cough. Occurrence of wheeze must be considered carefully as up to one third in the registry had documented asthma and half had significant bronchodilator-associated reversibility on spirometry.[@b23-tcrm-11-143] To further study this, Eden et al[@b24-tcrm-11-143] looked for the presence of asthma in patients with AATD. They performed an assessment of wheezing, bronchodilator responsiveness, occurrence of atopy, and the presence of an increased serum immunoglobulin E (IgE) level. The study illustrated that three or more of such markers were present in 22% of AAT-deficient patients as compared to 5% of COPD patients without AATD.[@b24-tcrm-11-143]

Pulmonary function usually illustrates an obstructive pattern, while arterial blood gas sampling shows normo--hypoxia at rest, with hypercapnia as disease advances.[@b23-tcrm-11-143] Importantly, chest radiography in early disease may be normal or may show minimal change. This has led to interest in detecting disease earlier and permitting greater quantitative assessment through computed tomography (CT) scans of the thorax. Consequently, the use of CT imaging in AATD has intensified for several reasons. First, it allows the detection of early disease before any appreciable loss of lung function by spirometry. Second, it permits an evaluation of the efficacy of therapeutic interventions such as augmentation therapy, and finally, it has increased our recognition of other associated pulmonary conditions such as bronchiectasis. While initial studies did not clearly reveal this association, work that followed showed that up to 40% of AATD individuals have some degree of coexistent bronchiectasis.[@b25-tcrm-11-143]--[@b27-tcrm-11-143]

Hepatic disease
---------------

Up to 15% of Z AATD individuals have demonstrated significant liver disease in the first two decades of life.[@b2-tcrm-11-143],[@b28-tcrm-11-143] Hepatocyte inclusion bodies, an effect of Z AAT protein polymerization, has been described from a histological perspective.

With its incidence being greatest in children, Z AAT-associated liver disease can present as abnormal serum liver enzymes, neonatal jaundice (most common), or cirrhosis. Importantly, while infants with the SZ phenotype show no signs of early liver disease, up to 8% may show abnormal liver function in their teenage years. Adults with documented liver disease in infancy were also found to be clinically well in later life.[@b28-tcrm-11-143],[@b29-tcrm-11-143]

Adult-associated Z AATD liver disease may present as chronic hepatic impairment or hepatocellular carcinoma.[@b28-tcrm-11-143],[@b30-tcrm-11-143] Up to one in ten AATD patients \>50 years of age will develop cirrhosis associated with late-onset symptomatic hepatitis. The relative age of onset for liver disease is increased in heterozygotes (MZ) when compared to homozygotes (ZZ) by almost fifteen years.[@b31-tcrm-11-143]

Other disease
-------------

AAT naturally inhibits proteinase 3 and therefore a link to Wegener's granulomatosis is described.[@b31-tcrm-11-143],[@b32-tcrm-11-143] A rare necrotizing skin panniculitis is also observed in clinical practice in some individuals with AATD. The presence of intracranial or abdominal vascular aneurysms and fibromuscular dysplasia has been suggested as being associated with AATD; however, direct causality has not been established.[@b33-tcrm-11-143] Renal disease ranging from IgA nephropathy to membranoproliferative glomerulonephritis can similarly occur in AAT-deficient states, with particularly increased rates in AATD patients with liver cirrhosis.[@b34-tcrm-11-143],[@b35-tcrm-11-143]

AAT augmentation therapy
========================

The rationale for AAT augmentation originated from our understanding of disease pathophysiology. Intravenous treatment with pooled purified human AAT with the intention of correcting the deficient state augmented both serum and lung epithelial levels of AAT.[@b36-tcrm-11-143]

In the late 1980s, plasma-purified AAT was safely delivered intravenously to patients with deficiency in order to achieve plasma levels exceeding a protective threshold of 11 μm.[@b37-tcrm-11-143] This target concentration was derived from levels detected in AATD SZ individuals, who if nonsmokers very rarely develop pulmonary disease.[@b38-tcrm-11-143] Increased levels of AAT coupled with increased anti-NE capacity both in serum and on the pulmonary epithelial surface were shown following intravenous AAT administration in these studies. While these early studies illustrated biochemical efficacy, there remained a need to demonstrate clinical benefit.[@b39-tcrm-11-143]

Potential clinical benefit from intravenous AAT replacement was demonstrated when a Danish group of AAT-deficient ex-smokers were studied against a comparable German cohort who had received augmentation. Those with a moderately reduced FEV~1~ (31%--65%) illustrated a significant but modest reduction in the annual rate of FEV~1~ decline (21 mL/year) with augmentation.[@b40-tcrm-11-143] While comparable results were noted within the NHLBI registry, importantly, this latter data set also illustrated a mortality benefit not identified in previous work.[@b41-tcrm-11-143]

Additional radiology-based work was performed by Dirksen et al[@b42-tcrm-11-143] who assessed thoracic CT changes in those receiving augmentation. While their data detected no significant difference (*P*=0.07), it importantly provided enough information to develop a power statistic and critically determine the number of AAT individuals needed for future clinical trials to conclusively illustrate a clinical effect using radiological end points.[@b42-tcrm-11-143] It was determined that approximately n=550 AAT-deficient individuals would be needed over a 24-month period to illustrate significant benefit from intravenous AAT augmentation on spirometry alone. Conversely, only n=130 would need to be examined to demonstrate radiological impact focused on CT indexes of emphysema. This was a significant breakthrough in the field, acknowledged by the US Food and Drugs Administration.[@b43-tcrm-11-143] Consequently, spirometry was considered a secondary efficacy end point in the study of augmentation therapy.

The EXAcerbations and Computed Tomography scan as Lung End points (EXACTLE) trial followed. This multicenter, randomized, placebo-controlled, double-blind, exploratory trial utilized CT densitometry and occurrence of exacerbations to assess the therapeutic effectiveness of weekly intravenous AAT augmentation over an approximately 2-year period. Radiological progression of emphysema was defined by a 15th-percentile change in lung density as derived from the CT voxel distribution histogram of the entire lung. Seventy-seven ZZ AATD patients were randomized to either 60 mg/kg AAT (Prolastin^®^; Talecris) or placebo. This study illustrated that CT was a sensitive and effective measure of emphysema progression. A number of statistical analyses were utilized in this study, with *P*-values ranging from 0.049 to 0.084, but all suggested at least a trend toward efficacy of augmentation therapy in reducing loss of lung density by AAT augmentation. It was felt, however, that this study suffered from being underpowered.[@b44-tcrm-11-143]

Following this, a multicenter, multinational, randomized controlled trial was conducted and recently completed. This study randomized ZZ AATD patients to receive AAT augmentation therapy (Zemaira, CSL Behring) intravenously 60 mg/kg weekly or placebo over 2 years, measuring CT scan lung density at regular study intervals (RAPID). Secondary end points included spirometry, exacerbations, and quality of life measurements. This study evaluated 180 subjects over the 2-year period and was followed with an extension study in which all study participants received active drug. The results showed that intravenous augmentation slowed emphysema progression by decreasing loss of lung density as measured by CT imaging. This is the first prospective data utilizing a novel radiological end point to conclusively demonstrate clinical efficacy of augmentation therapy.[@b39-tcrm-11-143]

Concerns about product purity and risks of transmissibility of infection through use of human plasma-derived AAT led to evaluation of transgenic and recombinant sources of AAT. Recombinant AAT was successfully produced in bacteria, such as *Escherichia coli*, and in yeast, as well as in transgenic sheep that were engineered to produce AAT in their milk.[@b45-tcrm-11-143]--[@b47-tcrm-11-143]

A major disadvantage to these recombinant protein forms of AAT is lack of glycosylation or abnormal glycosylation, which is associated with altered renal clearance. Consequently, when compared with plasma-purified AAT following intravenous administration, such forms are eliminated more rapidly. To overcome this particular issue, an inhaled product with an appropriate half-life on the pulmonary epithelial surface was considered and subsequently investigated. Aerosolization of plasma-purified AAT (Prolastin) and recombinant AAT were effective at delivery not solely to the alveolar surface but, critically, to the alveolar interstitium.[@b48-tcrm-11-143] Whether that is sufficient for clinical efficacy remains to be evaluated.

Currently available AAT preparations for augmentation include Aralast/Glassia (Baxter^®^), Prolastin-C (Grifols^®^), and Zemira (CSL Behring^®^), all of which are purified protein intravenous formulations taken from pooled human plasma.

Gene-based therapeutics has also been researched as an alternative to augment AAT levels. Thus far, the normal AAT gene has been successfully introduced into striated muscle cells in animal models with the use of an adeno-associated virus.[@b49-tcrm-11-143]--[@b51-tcrm-11-143] Alternatively, plasmid and recombinant adeno-associated virus (rAAV) vectors have been assessed for effective transgene delivery and some success is observed with intrapleural delivery of AAV vectors in murine and primate model systems. Long-term pleural expression of AAT mRNA has been shown to last up to 1 year posttreatment in such data sets.[@b52-tcrm-11-143] Brantly et al[@b53-tcrm-11-143] demonstrated that intramuscular injection of recombinant AAV in a dose-escalating fashion was not associated with any vector-associated adverse events. Sustained AAT levels at 12 months have now been proven and Phase II clinical trials show promise.[@b54-tcrm-11-143],[@b55-tcrm-11-143] Additionally, evidence by Brigham et al[@b56-tcrm-11-143] illustrate that plasmid--cationic liposomal delivery of a normal *AAT* gene to the respiratory epithelium of deficient patients produces potentially local therapeutic AAT concentrations and that *AAT* gene therapy, just like AAT protein therapy, may provide anti-inflammatory benefits. While significant progress has been made in this field, the relative roles of intrapleural and targeted airway delivery, micro-RNA-expressing vectors, and genome editing are all eagerly awaited.[@b57-tcrm-11-143]

Patient safety and tolerability
===============================

Distinguishing between safety and tolerability of any medicinal product is important. The safety of a medicine pertains to the medical risks conferred to the patient from its administration, which is commonly assessed in clinical trials through laboratory tests, measurement of vital signs, clinical adverse events, and other special safety tests, such as electrocardiograms, arterial blood gas levels, and radiology.[@b58-tcrm-11-143] Tolerability, however, represents the degree to which a subject can tolerate adverse effects. The investigation of safety and tolerability of any new therapy is a multidimensional challenge. It demands strict scope of evaluation coupled with an anticipated choice of variables to assess utilization of appropriate methods of data collection. Commonly used laboratory tests concerning clinical chemistry and hematology, vital signs, and clinical adverse events (diseases, signs, and symptoms) predominantly form the main body of the safety and tolerability data described for a particular drug or therapeutic intervention.

Patient outcomes from two major studies of patients following AAT augmentation therapy suggest that it appears well tolerated and is generally safe.[@b59-tcrm-11-143],[@b60-tcrm-11-143] Wencker et al[@b60-tcrm-11-143] reported the trial of n=443 augmentation therapy recipients, of whom 65 experienced a total of 124 adverse events. Most commonly encountered adverse reactions were relatively benign and self-resolving. These included chills, urticarial rashes, fatigue, nausea, and vomiting. Although specific adverse effects may be anticipated and specifically monitored for during therapy, the range of possible adverse effects is large, and new potentially unforeseeable effects remain possible. The trial data however are reassuring, given that 58,000 infusions resulted in only five severe side effects that necessitated hospital admission but importantly all had a complete recovery. Four patients suffered anaphylactic reactions and one patient developed congestive cardiac failure. Critically, no deaths or instances of hematologic viral transmission were observed.[@b60-tcrm-11-143]

Stoller et al[@b59-tcrm-11-143] reported on the NHLBI experience of n=747 patients receiving weekly AAT augmentation therapy for a period of seven years. The overall rate of adverse events was low at 0.02 per patient-month, with 83% of patients reporting no events. There were a total of 720 recorded adverse events, the most common of which included headache (47%), dizziness (17%), nausea (9%), and dyspnea (9%). It is important to note however that the data highlighted a lower rate of adverse events in participants receiving augmentation therapy less frequently than weekly. The rate of total adverse events decreased from 0.03 events per patient-month at weekly infusions to 0.024 events per patient-month at 2--3 weeks (*P*=0.020) and 0.005 events per patient-month at monthly infusions (*P*\<0.001). The study importantly was complicated by the recall of two α~1~-antiprotease batches in 1989 and 1991, which were associated with a clustering of adverse events. The events related to the flawed lots were excluded from the analysis of the NHLBI registry, and this may affect its comparability with other studies. The occurrence of serious adverse events and treatment discontinuations due to them are particularly important to register.

Meyer et al[@b61-tcrm-11-143] reported a rare IgE anaphylactic reaction following the third intravenous infusion of AAT. Specific IgE antibodies against Prolastin-HS were identified on serum analysis of the patient. Consequently, manufacturing modifications to Prolastin have subsequently led to the development of an updated α(1)-proteinase inhibitor product, designated Prolastin-C, which has demonstrated pharmacokinetic equivalence and a comparable safety profile to Prolastin without any reported life-threatening adverse events to date.[@b62-tcrm-11-143]

Adverse event monitoring is particularly important with augmentation therapy as long-term treatment is envisioned and an expected proportion of treatment withdrawals or natural deaths are expected. For such situations, survival analysis methods should be considered and cumulative adverse event rates calculated in order to avoid the risk of underestimation. Alternatively any new adverse effects may be screened by later-phase controlled trials, even if such trials generally would lack power for this purpose.[@b58-tcrm-11-143]

Patient outcomes and cost-effectiveness
=======================================

As shown above, augmentation therapy has been clearly shown to raise anti-protease serum and epithelial lining fluid levels above putative "protective threshold" values. Evidence suggests that such an approach slows lung function declines, may reduce infection or exacerbation rates, potentially enhance survival, and is generally well tolerated ([Table 2](#t2-tcrm-11-143){ref-type="table"}). In addition, a meta-analysis by Chapman et al[@b63-tcrm-11-143] supports the use of augmentation therapy in slowing the rate of lung function decline in patients with AATD, highlighting that patients with moderate obstructive disease as determined by spirometry are most likely to benefit. A further integrated analysis of two randomized controlled trials by Stockley et al[@b64-tcrm-11-143] demonstrated that intravenous augmentation therapy significantly reduced declines in lung density on CT imaging. Once-monthly and twice-weekly augmentation has also been studied, and most data to date support a weekly regimen.[@b60-tcrm-11-143]

However, while augmentation therapy has been associated with a significant potential increase in gain of life years, this benefit is adversely affected by smoking and comes at high financial cost. For instance, female ex-smokers gain an estimated mean of 7.14 years at a cost of US\$248, 361/year, compared to female nonsmokers who gain 9.19 years at a cost of US\$160,502/year. On the other hand, male ex-smokers gain 5.93 years at US\$142,250/year and nonsmokers 10.6 years at US\$59,234/year.[@b65-tcrm-11-143] In one publication, Gildea et al[@b66-tcrm-11-143] suggested that the cost of augmentation therapy would need to be reduced from US\$54,765 to US\$4,900 to be deemed a lifelong cost-effective therapy.

In order to address concerns over such high costs of therapy, the efficacy of longer intervals between therapy has been considered. Hubbard et al[@b67-tcrm-11-143] administered A1AT at 250 mg/kg monthly and demonstrated serum A1AT levels and anti-elastase activity within epithelial lining fluid within the protective range at 28 days postinfusion. In contrast, Barker et al[@b68-tcrm-11-143] adopted a fortnightly regimen and failed to demonstrate protective serum levels. Similarly, Cammarata et al[@b69-tcrm-11-143] failed to achieve adequate serum A1AT levels with monthly replacement regimes. While the flexibility of an increased-interval dosing regimen of augmentation therapy would significantly reduce the cost burden associated with augmentation and is attractive, this is unlikely to be fruitful as several studies have demonstrated high levels of variability in the trough concentrations of serum AAT when administered at intervals exceeding once weekly, which now remains the regimen of choice.[@b70-tcrm-11-143],[@b71-tcrm-11-143] Other methods of administration such as gene therapy, subcutaneous administration, or aerosolization of AAT may yet yield benefits in this regard.

An assessment of the direct medical costs of simply having AATD was performed by surveying members within the US Alpha One Foundation Registry. The mean annual estimated costs were found to be highest for ZZ AAT patients, at approximately US\$30,948/year but were even higher for the subgroup on augmentation therapy (US\$40,123/year).[@b72-tcrm-11-143] This initial study only reported total costs rather than the specific components of the direct medical costs. Use of augmentation accounted for more than half of all costs for the ZZ AAT individual, with other major contributors being prescription drugs, hospitalizations, health insurance, and physician visits.[@b73-tcrm-11-143]

In general, it is cited that the "estimated" annual cost for patients receiving augmentation therapy in the US is however even greater than these figures suggest and may be as high as approximately US\$120,000 annually. This is thrice the yearly cost for patients with COPD alone. While use of augmentation slows disease progression, consequently positively affecting hospital admission rates and lung transplantation, it is clearly an expensive therapy, with issues of access complicated by reported shortages and reimbursement concerns.[@b74-tcrm-11-143]

The benefit of AAT augmentation in ZZ-homozygote AAT patients is now becoming clearer; however, its role in Z heterozygotes (eg, MZ and SZ) remains uncertain. It is currently not recommended for MZ heterozygotes who have COPD.[@b75-tcrm-11-143] This is based on the absence of supporting evidence for efficacy in this cohort, and the fact that the target nadir serum levels for augmentation in ZZ homozygotes are below the usual AAT serum levels for MZ individuals. Recent evidence by Molloy et al[@b76-tcrm-11-143] has shown that MZ heterozygotes have significantly more airflow obstruction and COPD than MM individuals and that cigarette smoke exposure significantly augments this effect. Importantly, however, up to 10% of SZ heterozygotes have serum levels below the threshold of 11 μM and in this setting, the potential benefit of augmentation might be raised.[@b77-tcrm-11-143] The current pool of available evidence does not address this issue, and future work is required to examine potential benefits of augmentation in SZ individuals at risk of accelerated lung function decline and increased mortality.

The role for augmentation therapy in the setting of lung transplantation is a further challenge for future work.[@b78-tcrm-11-143] Limited evidence by King et al[@b79-tcrm-11-143] demonstrates an increased free elastase activity in bronchoalveolar lavage fluid of lung transplant recipients during lower respiratory tract inflammation, a phenomenon absent in the healthy state. Subsequent augmentation therapy inhibits elastase-mediated injury to the transplanted lung and hence should be considered for even the non-AATD setting. While increased oxidative stress in the AATD lung necessitates a double rather than single lung transplant in AATD, there persists a paucity of clinical evidence to inform transplant physicians about the merit of augmentation strategies for such patients during peri- or posttransplant clinical care.

Future challenges and conclusion
================================

Determining the efficacy of currently available AAT augmentation strategies for the treatment of deficiency remains a clinical priority. This will inevitably involve assessing the present dosage strategy to see whether better clinical effects can be achieved with higher doses. Trials assessing superiority or equivalence among the various forms of commercially available pooled AAT remain to be performed. Expanding the available evidence base with focus on safety and tolerability data for the various therapeutic options is important. With expected future increases in the use of AAT augmentation, not just for AATD-related lung disease but also for its use in AAT-related panniculitis and its emerging profile as an anti-inflammatory agent, specific concerns of safety and tolerability in at-risk populations (including immune-suppressed individuals, females of child-bearing potential, the elderly, and posttransplant population) will need to be considered. Finally, cost-effectiveness of intravenous augmentation therapy needs to be improved and attention given to other strategies such as gene therapy, aerosol administration, or subcutaneous administration of AAT to see whether they have comparable or improved efficacy and cost-effectiveness to what is now currently the gold standard of once-weekly intravenous therapy with plasma-purified AAT.
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###### 

Genotype variants in alpha-1 antitrypsin protein level and function

  Variant         Allele or mutation                                                      Features
  --------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Normal          *M*                                                                     Normal plasma levels (\>20 μmol/L), protein variants exist (eg, M1, M2, etc)
  Deficient       *Z or S*                                                                Common deficiency variants: "Z" and "S"; plasma levels: 5--6 μmol/L and 8--11 μmol/L, respectively
  Null            *QO~Lisbon~*, *QO~Dublin~*, *QO~Bolton~*, *QO~Cork~ Thr68IIe exon II*   No detectable circulating protein
  Dysfunctional   *Met358Arg*                                                             Pittsburgh mutation[@b3-tcrm-11-143]: protein is thrombin, rather than elastase inhibitor

###### 

Summary of clinical trials on alpha-1 antitrypsin augmentation therapy

  Trial design                        Trial reference                    Year                                                         Main outcome measures
  ----------------------------------- ---------------------------------- ------------------------------------------------------------ -----------------------------------------------------------------------
  Randomized                          Dirksen et al[@b42-tcrm-11-143]    1999                                                         Slower rate of lung tissue loss on CT and no change in FEV~1~ decline
  Dirksen et al[@b44-tcrm-11-143]     2009                               Slower rate of lung tissue loss on CT                        
  Observational                       Stone et al[@b80-tcrm-11-143]      1995                                                         Reduction in urine desmosine levels
  Seersholm et al[@b40-tcrm-11-143]   1997                               Reduction in FEV~1~ decline in cohort with FEV~1~ 35%--49%   
  NHLBI registry                      1998                               Reduction in FEV~1~ decline in cohort with FEV~1~ 35%--49%   
  Lieberman[@b81-tcrm-11-143]         2000                               Reductions in exacerbations                                  
  Wencker et al[@b82-tcrm-11-143]     2001                               Slower rate of FEV~1~ decline                                
  Tonelli et al[@b83-tcrm-11-143]     2009                               Slower rate of FEV~1~ decline                                
  Descriptive                         Gottlieb et al[@b84-tcrm-11-143]   2000                                                         No reduction in elastin degradation rate
  Stockley et al[@b85-tcrm-11-143]    2002                               Reduction in sputum LTB4                                     

**Note:** Readers may also refer to Stoller et al[@b86-tcrm-11-143] for more information.

**Abbreviations:** CT, computed tomography; FEV~1~, Forced expiratory volume in 1 second; LTB4, Leukotriene B4; NHLBI, National Heart, Lung, and Blood Institute.
